Lead (212PB) lapemelanotide zapixetan
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Lead (212PB) lapemelanotide zapixetan
- Molecular weight
- 1,916.95
- Lead (212pb) lapemelanotide zapixetan
- lead 212pb lapemelanotide zapixetan
- Plomb (212pb) lapemelanotide zapixetan
- plomb 212pb lapemelanotide zapixetan
- Plomo (212pb) lapemelanotide zapixetan
- plomo 212pb lapemelanotide zapixetan
- ChEMBL ID
- CHEMBL6068068
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tide; -xetan
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 123
- Molecular formula
- C79H117N25O18Pb
- Natural product
- No
Related records
Trials (9)
- [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
- A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Phase 0/1 Study of 212Pb-NG001 in mCRPC
- Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
- Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
In development for (1)
- Neoplasm Phase 2